Our efficacy studies demonstrated that RT combined with Y332D therapy exhibited potent antitumor activity in multiple murine tumor models, outperforming Y332D or RT monotherapies and RT combined with α‐TGF‐β or α‐VEGF therapy. This evidence concerns the gene TGFB1 and neoplasm.